Brief: Mateon Q3 net loss $3.2 million
14/11/2016 14:00
Nov 14 (Reuters) - Mateon Therapeutics Inc MATN.O
* Mateon therapeutics inc - for q3 of 2016, mateon reported
a net loss of $3.2 million compared to a net loss of $3.6
million for q3 of 2015
* Mateon therapeutics - currently believes cash, cash
equivalents sufficient to fund operations through availability
of key clinical data from focus study
* Mateon provides corporate update and reports third quarter
2016 financial results
Source text for Eikon: ID:nGNXNKTEDa
Further company coverage: MATN.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas